Abstract
No AccessJournal of UrologyAdult Urology1 Mar 2018Editorial Comment Matthew Mossanen and Adam S. Kibel Matthew MossanenMatthew Mossanen More articles by this author and Adam S. KibelAdam S. Kibel More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.10.055AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Editorial Comment." The Journal of Urology, 199(3), p. 712 References 1 : High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol2014; 11: 308. Google Scholar 2 : Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet2017; 389: 815. Google Scholar 3 : The present and future of biomarkers in prostate cancer: proteomics, genomics, and immunology advancements. Biomark Cancer2016; 8: 15. Google Scholar © 2018 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 199Issue 3March 2018Page: 712 Advertisement Copyright & Permissions© 2018 by American Urological Association Education and Research, Inc.MetricsAuthor Information Matthew Mossanen More articles by this author Adam S. Kibel More articles by this author Expand All Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
